{
    "symbol": "ABBV",
    "slug": "abbv",
    "display_name": "ABBV",
    "category": "stocks",
    "region": "US",
    "description": null,
    "url": "https://finscans.com/fr/asset/abbv",
    "lang": "fr",
    "as_of": "2026-07-01T11:09:03+00:00",
    "stats_30d": {
        "total_signals": 1,
        "bullish": 1,
        "bearish": 0,
        "neutral": 0,
        "explicit": 0,
        "inferred": 1,
        "avg_impact": 5,
        "avg_confidence": 70,
        "last_signal_at": "2026-07-01 10:10:05",
        "article_count": 1
    },
    "top_catalysts": [
        {
            "text": "Le rejet de Relfydess élimine un concurrent",
            "count": 1
        }
    ],
    "top_risk_factors": [
        {
            "text": "D'autres concurrents pourraient encore menacer Botox",
            "count": 1
        },
        {
            "text": "La FDA pourrait bientôt approuver d'autres alternatives au Botox",
            "count": 1
        }
    ],
    "recent_signals": [
        {
            "signal_at": "2026-07-01 10:10:05",
            "sentiment": "Bullish",
            "impact_score": 5,
            "confidence_score": 70,
            "mention_type": "inferred",
            "timeframe": "short-term",
            "region": "US",
            "reasoning": "La franchise Botox d'AbbVie fait face à une concurrence réduite à court terme aux États-Unis après que la FDA a rejeté Relfydess de Galderma. Cela assure la domination du marché de Botox.",
            "article": {
                "title": "Les actions de Galderma chutent après le rejet de Relfydess, rival de Botox, par la FDA",
                "url": "https://finscans.com/fr/news/les-actions-de-galderma-chutent-apres-le-rejet-de-relfydess"
            }
        }
    ]
}